All posts from in,

Ocata Therapeutics' (OCAT) CEO Paul Wotton on Q2 2015 Results - Earnings Call Transcript


Good day, ladies and gentlemen, and welcome to the Ocata Second Quarter 2015 Update Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to introduce your host for today's conference, John Woolford. Please go ahead, sir.

John Woolford - Investor Relations

Thank you and welcome to Ocata Therapeutics second quarter 2015 corporate update call. My name is John Woolford from Westwicke Partners. I'm joined here today with several members of Ocata's senior management team, Paul Wotton, President and CEO; Ted Myles, CFO and COO; and Eddy Anglade, CMO.

Before we get started, I just want to remind everyone that we will be making forward-looking statements as defined under the Federal Securities Laws. Actual results could vary materially, factors that could cause actual results to vary materially are described in our filings with the Securities and Exchange Commission. Most recently our Form 10-K is filed on March 16, 2015, and is updated on our Form 10-KA as filed on April 10, 2015, and most recently, our Form 10-Q as filed earlier today, August 6, 2017. You should pay particular attention to the risk factors contained in documents we filed from time-to-time with the Securities and Exchange Commission.

The risks identified there in, as well as others not identified by the company could cause the company's actual results to differ materially from those expressed in any forward-looking statements. Those of you listening by webcast, there options to submit question by the website. At the end we will answer selected questions submitted in that manner.

I'll now turn the call over to Dr. Paul Wotton, Ocata's President and CEO. Paul?

Paul Wotton - President & CEO

Thank you, John, good afternoon everyone and thank you for joining us on today's call. I'm very pleased with the continued progress we made in the second quarter this fiscal year. And I'd like to start the call by highlighting some of the key events from the quarter.

First, we continue to make significant progress with our RPE program and remain on-track to initiate a Phase II study in dry AMD in the third quarter and a pivotal study in SMD in the second half of this year. We've had success in increasing the number of study sites and obtaining RPE approvals required to those patients now. We announced the publication of data that was generated by our partners in South Korea on four patients. This data was supportive of that previously announced RPE clinical results which have not been extended to a geographically distinct population. And so that our current RPE program is globally relevant for the potential treatment of both dry AMD and SMD.

Following our up listing to the NASDAQ global market, we have remained visible to the investment community, presenting at several investor conferences and our shares were added to the Russell 2000, 3000, and Microcap indices. Our daily share trading volume has tripled year-over-year in the second quarter and the increased liquidity also makes the company more investible to potentially new institutional investors. We continue to strengthen our IP position, most notably in an RPE program with five new patents this quarter, and we continue to strengthen our IP position in other critical areas of the business as well.

And finally, we are significantly strengthened our balance sheet with a $30 million common stock offering, attracting institutional capital was the key goal for the first half of 2015, and I'm pleased that we completed this offering during a difficult time in the market which will subsequently become more challenging, and believe that we will have access to enough capital to fund the company through our next major inflexion point. We continue to be pleased with the progress of developing a content, the leading regenerative ophthalmology company.